Tissue inhibitor of metalloproteases (TIMPs) are inhibitors of matrix metalloproteinases (MMPs) that regulate tissue extracellular matrix (ECM) turnover. TIMP4 is highly expressed in adipose tissue, its levels are further elevated following high-fat diet, but its role in obesity is unknown. Eight-week old wild-type (WT) and Timp4-knockout (Timp4 −/− ) mice received chow or high fat diet (HFD) for twelve weeks. Timp4 −/− mice exhibited a higher food intake but lower body fat gain. Adipose tissue of Timp4 −/--HFD mice showed reduced hypertrophy and fibrosis compared to WT-HFD mice. Timp4 −/--HFD mice were also protected from HFD-induced liver and skeletal muscle triglyceride accumulation and dyslipidemia. Timp4 −/− -HFD mice exhibited reduced basic metabolic rate and energy expenditure, but increased respiratory exchange ratio. Increased free fatty acid excretion was detected in Timp4 −/− -HFD compared to WT-HFD mice. CD36 protein, the major fatty acid transporter in the small intestine, increased with HFD in WT but not in Timp4 −/− mice, despite a similar rise in Cd36 mRNA in both genotypes. Consistently, HFD increased enterocyte lipid content only in WT but not in Timp4 −/− mice. Our study reveals that absence of TIMP4 can impair lipid absorption and the high fat diet-induced obesity in mice possibly by regulating the proteolytic processing of CD36 protein in the intestinal enterocytes.
provides structural support for the tissues as well as regulating cell functions by activating various signaling mechanisms directly or indirectly by sequestering signaling molecules 9 .
Tissue inhibitor of metalloproteinases (TIMPs) are best known as endogenous inhibitors of matrix metalloproteinases (MMPs) and disruption of the MMP-TIMP balance influences the rate of ECM turnover 10 . A number of MMPs (e.g. MMP2, MMP9, and MMP13) and the four TIMPs (TIMP1-4) are expressed in the adipose tissue 11, 12 , and they have been reported to be involved in development of obesity and associated complications [13] [14] [15] [16] . TIMP1 has been reported to be an adipokine which is upregulated in adipose tissue under obese conditions, increases preadipocyte differentiation and adipocyte fat accumulation and can be used as a predictor of adiposity in humans [17] [18] [19] . Timp1-deficient mice are resistant to diet-induced obesity 20 , whereas Timp2-knockout mice are prone to diet-induced obesity 21 . Concomitant deficiency in Timp3 and insulin receptor resulted in adipose tissue inflammation and fatty liver, whereas macrophage-specific TIMP3 overexpression was protective against insulin resistance 22, 23 .
TIMP4 is highly expressed in the adipose tissue 24 , however the role of TIMP4 in adipose tissue biology and obesity has not been explored so far. In this study, we investigated the role of TIMP4 in obesity using Timp4-deficient mice and found that TIMP4 promotes high fat-induced obesity, fatty liver and dyslipidemia possibly by promoting intestinal lipid absorption by preventing proteolytic processing of CD36, the cell surface fatty acid transporters in enterocytes.
Materials and Methods
Animal experiment. Heterozygous Timp4 knock-out mice (C57BL/6 background; Texas A&M Institute for Genomic Medicine) were bred to generate wild-type (WT) and Timp4 knock-out mice (Timp4 −/− ). Eight weeks old male mice from each genotype were fed either chow-diet (10% calories from fat; D10012M from Research diets) or high-fat diet (HFD, 60% calories from fat; TD06414 from Envigo) ad libitum for twelve weeks. Body weights were measured weekly and cumulative food intake was measured weekly twice. Body composition analysis, basic metabolic rate studies and glucose tolerance tests were performed between 10 th and 12 th week of the study. At 12 weeks, mice were euthanized and tissues were collected after overnight fasting (twelve hours) or in fed-sate. Blood was collected by cardiac puncture, plasma and various tissues were stored at −80 °C for further analyses, or formalin-fixed and paraffin-embedded for histological analysis. All animal procedures were approved by the University of Alberta Animal Care and Use Committee, and in accordance with guidelines of the Canadian Council on Animal Care.
Body composition analysis.
Total body fat mass and lean mass were determined by using Echo-MRI (Echo Medical Systems, Houston, Texas). Fat mass and lean mass percentages were calculated from the whole-body weights.
Basic Metabolic Rate (BMR). Basic metabolic rate (VO 2 consumption), VCO 2 release and energy expenditure (EE) were measured by indirect calorimetry for 24 hours in wild-type and TIMP4KO mice belonging to both chow-fed and high-fat-fed groups (Comprehensive Laboratory Animal Monitoring System, Columbus Instruments, Columbus, OH). Respiratory exchange ratio (RER) was calculated from VCO 2 release-to-VO 2 consumption ratio (VCO 2 release/VO 2 consumption). Physical activity of mice in the metabolic cages was measured by recording movements along the X-, Y-and Z-axes using infrared sensors 25 . BMR was corrected for both body weight and lean body mass obtained from body composition analysis.
Oral Glucose Tolerance test. For glucose tolerance test (OGTT), mice were fasted for six hours and were orally given 20% glucose solution (dose: 2 g/Kg body weight). Blood was drawn from tail vein at 0, 15, 30, 60 and 120 minutes after the glucose load and blood glucose was measured by commercially available glucose strips (Contour Next, Bayer).
Plasma biochemical measurements and Pancreatic Lipase Activity. Plasma TG (Wako Chemicals),
FFA (Abcam), total, HDL and VLDL/LDL cholesterol levels were measured using commercially available kits according to the manufacturer's instructions (Abcam). Plasma insulin was measured by ELISA (EMD Millipore). Pancreatic lipase activity was measured in the pancreatic tissue homogenates according to the manufacturer's protocol (Abcam #ab102524).
Immunohistochemistry. Epididymal adipose tissue, brown adipose tissue, liver, small intestines (3 different regions from proximal 10 cm at regular intervals) were formalin-fixed overnight at 4 °C and embedded in paraffin. Five micron sections were taken and stained for haematoxylin & eosin (H&E) to study tissue morphology. Picrosirius red (PSR) staining was used to visualize fibrillary collagen as reported previously 26 . Adipocyte size was measured in H&E sections using ImageJ software (100 cells/mouse, n = 4/group). For Oil Red O (ORO) staining of tissue neutral lipids, liver and skeletal muscle were embedded in tissue freezing medium immediately after dissection and stored at −80 °C. Five micron sections were used for staining and processed according to the protocol described previously 27 . Liver sections were stained with ORO for 15 minutes whereas skeletal muscle was stained for an hour. Adipose tissue inflammation was determined by staining for macrophages (F4/80 antibodies; AbD Serotec #MCA). Pancreas and small intestine sections were stained for TIMP4 (Abcam #ab51207) and also for pancreatic lipase (Santacruz #sc-393085) and CD36 (Novus Biologicals #NB400-144) respectively.
Western blotting. Tissues were homogenized in ice-cold sigma buffer (Sigma Aldrich #C3228) with protease and phosphatase inhibitor cocktails. Enterocytes were harvested from the proximal segment of the small intestine (proximal 10 cm) after the intestine was rinsed with cold PBS to remove luminal contents. Homogenates were centrifuged at 1000 × g for 15 minutes at 4 °C and supernatants were collected. Protein concentration was determined by DC protein assay kit (Bio-Rad #5000116) and 40 μg of protein were resolved by electrophoresis on SDS-8% polyacrylamide gels. Proteins were transferred to PVDF membranes and were detected by the following primary antibodies: TIMP4 (Abcam #ab51207) and CD36 (Novus Biologicals #NB400-144). Respective HRP-conjugated secondary antibodies were used to detect immunoreactivity. Immunoreactive proteins were visualized using the ECL kit and band intensities were quantified by ImageJ software. Coomassie blue-stained gel was used as internal loading controls. mRNA expression analyses. RNA was extracted from adipose tissues, liver and enterocytes using TRIzol reagent (Life technologies). cDNA expression of the following genes was measured as described previously using Taqman RT-PCR (Thermo Fisher Scientic & Applied Biosystems) 28 Hepatic, skeletal muscle and fecal lipid quantifications and Thin Layer Chromatography (TLC). Liver and quadriceps muscle were homogenized in PBS and lipids were extracted by modified Folch's method 25 . TG and cholesterol were measured using the commercially available kits (Wako and Abcam, respectively). Feces were collected after 24 hours and dried by lyophilizing overnight. For fecal TG analysis, total lipid was extracted and quantified as described above. TLC analysis was carried according to the protocol described previously using 100 mg of dried feces 30 . Statistics. Data are presented as dot-plot as well as averaged data as mean ± S.E.M. Statistical analyses were performed using two-way ANOVA followed by Tukey's post-hoc test, or student t-test as indicated. Statistical significance was recognized at P < 0.05.
Results
Timp4-deficient mice resist high fat diet-induced visceral obesity. TIMP4 protein levels increased significantly (by 77%) in the epidydimal adipose tissue of high fat diet-fed WT mice (WT-HFD) mice ( Fig. 1A) , although Timp4 mRNA expression was not altered significantly ( Fig. 1B) . To investigate whether the increase in TIMP4 contributes to adipose tissue fat deposition and obesity, we fed WT and age-matched Timp4 −/− mice HFD for 12 weeks. Prior to the start of HFD protocol, Timp4 −/− mice exhibited significantly greater food intake ( Fig. 2A ), but a significantly higher body weight compared to the age-matched WT mice ( Supplementary  Figure 1) , primarily due to a greater lean mass but lower fat mass ( Fig. 2G ). During the 12 weeks of HFD or chow feeding, chow-fed mice of both genotypes showed a similar rate of body weight gain, but Timp4 −/− mice receiving HFD showed a reduced rate of weight gain compared to WT-HFD mice. Consistent with the leaner appearance of Timp4 −/− -HFD mice (Fig. 2B ), the size of the visceral (epidydimal) fat pads were significantly reduced in these mice compared to WT-HFD ( Fig. 2C,D ), but no difference was observed in retroperitoneal ( Fig. 2E ) or inguinal fat pad size ( Fig. 2F, Supplementary Figure 3 ) between the two HFD groups. We performed Echo-MRI to determine the body mass composition. Chow-fed Timp4 −/− mice showed a significantly lower body fat percentage compared to chow-fed WT mice ( Fig. 2Gii ). Consistently, HFD-fed Timp4 −/− mice exhibited a significantly lower body fat content ( Fig. 2Gi ) which comprised a lower percentage of total body weight ( Fig. 2Gii ), but a higher lean mass content ( Fig. 2Hi ) that comprised a higher percentage of the total body weight ( Fig. 2Hii ) compared to parallel WT groups (Fig. 2G ). These results indicate that Timp4 gene deletion was associated with decreased body fat accumulation despite increased food intake.
Timp4-deficiency reduced white adipose tissue hypertrophy and reduced inflammation.
To gain more mechanistic insight, we next examined the impact of Timp4-deficiency on epidydimal adipose tissue morphology. Despite the significant decrease in body fat percentage in chow-fed Timp4 −/− mice, these mice showed a higher percentage of large-sized adipocytes in the epidydimal fat compared to chow-fed WT mice (Fig. 3A,B ). This could possibly result from impaired pre-adipocyte recruitment or differentiation in chow-fed Timp4 −/− mice leading to TG accumulation in the existing adipocytes rather than generation of new adipocytes. In contrast to chow-fed mice, the lower body fat content in HFD-fed Timp4 −/− mice was associated with smaller adipocyte size when compared to that of HFD-fed WT mice ( Fig. 3A and B ).
Increased collagen fiber deposition ( Fig. 3C ) and collagen type I expression ( Fig. 3D) were observed in WT-HFD but not in Timp4 −/− -HFD adipose tissue. In addition, expression of inflammatory cytokines Tnfα, Il-6 and Mcp1 were elevated in WT-HFD but not in Timp4 −/− -HFD adipose tissue ( Fig. 3Ei-iii) . Further, macrophage infiltration was increased only in WT-HFD epidydimal fat evident from the crown-like appearance of adipocytes ( Fig. 3Fi-iiii) . The HFD-induced rise in expression of inflammatory markers did not reach statistical significance in Timp4 −/− mice, while macrophage infiltration was markedly lower in these mice compared to WT-HFD mice (Fig. 3F ). Timp4 ablation did not alter the expression of other Timp genes and genes related to lipid metabolism (Ucp1, Elovl3, Acc1α, Dgat1 and Srebp1) in the epidydimal adipose tissue of chow-fed or HFD-fed Timp4 −/− mice, but significantly increased Dgat2 in Timp4 −/− -HFD adipose tissue ( Supplementary Figure 2) . These results indicate that Timp4 deficiency suppresses hypertrophy, fibrosis and inflammation in epidydimal adipose tissue upon HFD-feeding.
Obesity-induced hepatic steatosis was suppressed in Timp4-deficient mice. Although Timp4
gene expression is negligible in the liver (data not shown), because altered adipose tissue function can significantly affect the hepatic function, we investigated the hepatic lipid content, histology and expression of genes related to lipid metabolism. The chow-fed mice of either genotype showed comparable hepatic cellular morphology (Fig. 4A) , whereas hepatic lipid content was significantly reduced in Timp4 −/− -HFD compared to WT-HFD mice as assessed by H&E (Fig. 4A) , Oil Red-O staining (Fig. 4B ) and the macroscopic appearance of the liver that appears more white in WT-HFD but not in Timp4 −/− -HFD (Fig. 4C ). Liver TG was significantly elevated in WT-HFD but not in Timp4 −/− -HFD mice compared to the corresponding chow-fed groups (Fig. 4D) , while hepatic cholesterol levels were comparable among all groups (Fig. 4E ). HFD also induced expression of lipogenic (Scd1) and lipid oxidation (Pparα) genes, in WT but not in Timp4 −/− mice ( Fig. 4Fi-ii) . Hepatic fibrosis was not detected in any group ( Supplementary Figure 4) . Expression of Timp3, but not Timp1 or Timp2, was elevated in chow-fed Timp4 −/− mice, although the expression of all three Timp mRNAs was comparable between HFD-fed mice of either genotype ( Supplementary Figure 4) . Along with reduced TG levels, skeletal muscle TG content was also markedly lower in Timp4 −/− -HFD compared to WT-HFD mice (Fig. 4G ). HFD-mediated induction of plasma cholesterol, fatty acids and hyperinsulinemia were suppressed in Timp4-deficient mice. Plasma TG levels were comparable among all groups (Fig. 5A) , whereas the HFD-induced rise in free fatty acid and total LDL-cholesterol levels (LDL + VLDL) were significantly blocked in Timp4 −/− compared to WT mice (Fig. 5B,C) . Plasma total cholesterol and HDL cholesterol similarly increased with HFD in both genotypes (Fig. 5D,E) .
Since Timp4 −/− HFD mice showed reduced adiposity and plasma FFAs, we investigated if this led to improved obesity-associated glucose intolerance. Fasting glucose levels were comparable between the chow-fed and the HFD-fed groups, however, the HFD-induced rise in blood glucose was greater in Timp4 −/− mice (Fig. 6A) . Oral glucose tolerance test revealed that chow-fed Timp4 −/− mice have significantly lower glucose levels at 30 minutes and 60 minutes compared to WT-chow mice (Fig. 6B) although the difference in total glucose AUC (area under the curve) did not reach statistical significance (Fig. 6C ). However, after 12 weeks of HFD, Timp4 −/− and WT mice exhibited the same degree of glucose intolerance (Fig. 6B,C) indicating that the reduced adiposity in Timp4 −/− -HFD mice did not exert protection against glucose intolerance. Plasma insulin levels were similar in chow-fed WT and Timp4 −/− mice, while the high fat-induced rise in insulin was only detected in WT but not in Timp4 −/− mice (Fig. 6D ).
Brown Adipose Tissue (BAT) content was unaltered in Timp4 −/− mice. The reduced body fat gain despite increased food intake in Timp4 −/− mice could be due to increased energy expenditure and enhanced BAT thermogenesis. We assessed the histomorphometery of BAT tissue as well as expression of genes encoding regulatory proteins of thermogenesis (Ucp1) and brown adipose tissue fat accretion (Elovl3) in the HFD-fed mice. We found less accumulation of fat in Timp4 −/− BAT compared to the corresponding WT (assessed by the smaller size of adipocytes), a similar pattern to what we observed in white adipose tissue (Supplementary Figure 5A) . Ucp1 expression was comparable among all groups ( Supplementary Figure 4Bi ). Elovl3 mRNA expression were similar between WT-HFD and Timp4 −/− -HFD mice, although its HFD-induced rise was significantly greater in Timp4 −/− mice ( Supplementary Figure 5Bii) . Consistent with these observations, body temperature in HFD-fed Timp4 −/− mice was similar to WT-HFD mice (36.6 ± 0.21 °C vs 36.3 ± 0.27 °C).
Timp4 −/− mice have reduced basic metabolic rate (BMR), energy expenditure (EE) and respiratory exchange ratio (RER). Since BAT analysis did not reveal increased thermogenesis in Timp4 −/− mice, we investigated whether the basic metabolic rate (BMR) and the related parameters were altered in these mice. In contrary to our anticipation, Timp4 −/− chow fed mice showed significantly lower BMR compared to WT-chow-fed mice during night when data were normalized to whole body mass (Fig. 7A) . When BMR was normalized to lean mass, Timp4 −/− -HFD mice further showed reduced BMR at day and night, as well as the observed difference between chow-fed groups (Fig. 7B ). This could be due to the varying body fat content in HFD groups which resulted in different BMR values when BMR was normalized to whole body weight whereas to lean body mass. Consistently, night time energy expenditure (EE) was significantly lower in chow and high fat-fed Timp4 −/− compared to the corresponding WT mice (Fig. 7C) . Interestingly, while volume CO 2 was similar between the two genotypes ( Fig. 7D ), respiratory exchange rate was greater in Timp4 −/− chow compared to WT-chow mice, but not different between the HFD groups (Fig. 7E ). Chow-fed and HFD-fed Timp4 −/− showed similar physical activity (day and night) compared to the respective WT mice (Supplementary Figure 6 ). Timp4 −/− mice have defective lipid absorption and reduced CD36 protein levels. Increased food intake along with decreased BMR should lead to increased body fat and severe obesity, but in contrast, Timp4 −/− mice exhibit decreased body fat and reduced obesity following HFD feeding. This suggests that lipid absorption and/or digestion could be impaired in Timp4 −/− mice. Fecal TG levels showed increased trend in the Timp4 −/− chow-fed mice when compared to WT-chow-fed mice (Fig. 8A) , whereas fecal TG levels were significantly increased in WT-HFD but not in Timp4 −/− -HFD compared to corresponding chow-fed groups (Fig. 8A ). Further analysis of fecal lipid profile by TLC demonstrated similar lipid contents between chow-fed WT and Timp4 −/− mice (Fig. 8Aii ). Interestingly, Timp4 −/− -HFD mice showed a striking increase in fecal free fatty acid levels with unaltered TG, cholesteryl esters, and free cholesterol levels compared to WT-HFD group (Fig. 8Aiiii) . These data suggest that when exposed to high fat diet, Timp4-deficiency is associated with suppressed fatty acid absorption.
CD36 is a major fatty acid transporter, and since we found reduced fatty acid absorption in Timp4 −/− mice, we investigated if CD36 levels are altered in Timp4-deficient mice. We assessed the expression of CD36 in the proximal small intestine (duodenum) by immunofluorescent staining (Fig. 8B) and immunoblotting ( Fig. 8C ) and found that CD36 protein levels are significantly lower in enterocytes of chow-fed Timp4 −/− compared to WT mice, and the marked HFD-induced rise in CD36 levels observed in WT mice was not detected in Timp4 −/− mice. Cd36 mRNA, on the other hand, is increased similarly in the enterocytes of the proximal intestine following HFD in both genotypes (Fig. 8D) . Moreover, lipid content in enterocytes from Timp4 −/− -HFD mice was significantly lower than that in WT-HFD (Fig. 8E) . Interestingly, TIMP4 is expressed in the enterocyte of small intestine and its protein and mRNA levels are elevated with high-fat diet in WT mice ( Supplementary Figure 7A,B) . These data support the notion that TIMP4 could be responsible for post-translational regulation of CD36 and fat absorption in the small intestine.
We further assessed whether Timp4-deficiency alters fat digestion since TIMP4 is also expressed across the pancreas of WT mice and its levels are increased with high fat diet (Supplementary Figure 7C) . Examining pancreatic lipase levels and activity revealed that the HFD-induced rise in lipase levels were similar in both genotypes (Supplementary Figure 7D) , while HFD induced a rise in lipase activity in WT but not in Timp4 −/− mice, although the difference between WT-HFD and Timp4 −/− -HFD mice did not reach statistical significance (Supplementary Figure 7D) . 
Discussion
This study is the first to report the role of TIMP4 in high-fat diet-induced obesity. Timp4 gene deletion suppressed HFD-induced weight gain despite increased food intake and decreased BMR. Timp4 −/− mice fed HFD exhibit defective lipid absorption leading to reduced adipocyte hypertrophy, fibrosis, and diminished hepatic steatosis and dyslipidemia. Suppressed lipid absorption in Timp4 −/− mice is associated with reduced CD36 protein levels in the small intestine and reduced lipid content in the enterocytes. CD36 is a membrane protein and acts as translocator of fatty acid and oxidized sterols across the cell membrane 31 . CD36 is expressed mostly in the proximal region of the small intestine and shown to be important for FA uptake as well as secretion and clearance of intestinal derived lipoproteins 32 . The decreased CD36 protein, but not its mRNA levels in the small intestine of Timp4 −/− mice could be due to elevated MMP activities in the absence of MMP-inhibitory function of TIMP4, leading to cleavage of the membrane-bound CD36 in this region as has been reported for the heart and spleen 33, 34 , and as recently reported that CD36 can be cleaved by MMP9 34 .
Adipose tissues express various MMPs and TIMPs which have been reported to be dysregulated in obesity 12 . Inhibition of MMPs impairs adipose tissue development, decreases adipocyte hypertrophy and increases collagen deposition 35, 36 . TIMP1 has been linked to adiposity in humans, and recombinant TIMP1 inhibited preadipocyte differentiation and to decrease HFD-induced adipocyte hypertrophy 19, 37 , and TIMP1 gene deletion increased fecal caloric excretion 37 . Loss of Timp2, on the other hand, increased susceptibility to HFD-induced obesity 38 . Timp3 gene deletion increased adipose tissue inflammation whereas macrophage overexpression of TIMP3 resulted in protection from inflammation 22, 23 . HFD induced a rise in TIMP4 protein but not its mRNA levels in the adipose tissue. This could be due to post-transcriptional regulation of TIMP4 protein or perhaps a greater stability (half-life) of TIMP4 protein compared to its mRNA. Decreased body fat accumulation in Timp4 −/− -HFD mice could be attributed to decreased systemic entry of lipids due to impaired lipid absorption. Although defective fat absorption appears to be the main mechanism underlying the observed phenotype, decreased insulin levels in HFD-fed Timp4 −/− mice could also contribute to the decreased adipose tissue depots in these mice since insulin can induce hepatic lipogenesis, increase circulatory TG levels and TG uptake by the adipose tissue in addition to its lipogenic effect on adipose tissue. Decreased lipid digestion cannot be completely ruled out in HFD-fed Timp4 −/− mice as these mice showed a strong trend in decreased pancreatic lipase activity compared to HFD-fed WT mice.
With respect to our observations in the Timp4 −/− chow fed mice, lack of TIMP4 can lead to increased extracellular matrix turnover and deposition, which can in turn limit adipose tissue expansion as reported previously 35, 36 leading to an increase in the adipocyte size as we observed in chow-fed Timp4 −/− these mice. These observations suggest that TIMP4 is important for the maintenance of adipose tissue homeostasis under normal conditions. Timp4 −/− chow fed mice showed similar features as the HFD-fed Timp4 −/− mice in terms of increased food intake, decreased body fat and BMR, but they did not exhibit an overt defect in lipid digestion or absorption compared to WT-chow fed mice. However, the lower fecal TG and free fatty acid content, and enterocyte CD36 protein levels compared to WT-chow fed mice, although did not reach statistical significance, could underlie the enhanced susceptibility of Timp4 −/− mice to compromised lipid absorption when exposed to high fat diet.
Timp2 −/− male mice develop obesity-induced insulin resistance leading to diabetic state due to pancreatic β-cell exhaustion, whereas macrophage-specific TIMP3 expression protects from insulin resistance 21, 22 . We found that Timp4 −/− chow-fed mice show lower plasma glucose levels (up to 60 minutes following glucose loading) despite normal insulin levels and also have lower glucose levels after glucose load at 30 and 60 mins. This could be due to increased systemic utilization of glucose secondary to lower availability of lipid stores for energy production. This is consistent with the increased RER in Timp4 −/− chow-fed mice. Timp1 −/− mice have unaltered BMR, whereas mice with macrophage-specific overexpression of TIMP3 showed a small increase in BMR 22, 37 . The decreased BMR in Timp4 −/− -HFD mice indicates that these mice have reduced energy expenditure, and that enhanced energy expenditure (possibly through increased BAT activity) is not the cause of their reduced adiposity. Interestingly, Timp4 −/− HFD-fed mice are not protected from obesity-induced glucose intolerance despite their decreased body fat, plasma TG and fatty acids, which have been linked to glucose intolerance through impairing insulin signaling; however, Timp4 −/− -HFD mice are protected from hyperinsulinemia and accumulation of intramuscular TG.
MMP inhibitors have been shown to protect mice from HFD-induced fatty liver and shown to increase Pparα gene expression 39 . Hepatic TIMP1 and TIMP2 levels are elevated in obesity-related non-alcoholic fatty liver disease (NAFLD), and TIMP1 has been shown to mediate HFD-induced hepatic steatosis in mice 37 . Macrophage-specific overexpression of TIMP3 protected mice from hepatic steatosis 22, 23 . In contrast to the high expression levels of Timp1, Timp2 and Timp3 in liver, Timp4 levels in liver is negligible, suggesting that it may not play a role in hepatic ECM turnover, and absence of hepatic fibrosis in Timp4 −/− livers is likely secondary to the reduced fat absorption, and the subsequent suppression of adipocyte hypertrophy and inflammation. Hepatic TG levels are regulated by the rate of synthesis, secretion into plasma, in VLDL, and oxidation. Timp4 −/− mice have reduced hepatic TG stores. Because plasma fatty acid levels were low in Timp4 −/− mice particularly under high-fat conditions, hepatic esterification and secretion of TG would be expected to be decreased leading to the observed lower hepatic TG in these mice. Additionally, upregulation of Pparα, expression together with decreased expression of Scd1 suggests plausible increase in fatty acid oxidation and decrease in fatty acid synthesis in Timp4 −/− -HFD mice, which might have contributed to the observed decrease in hepatic TG stores 40, 41 . The protective effects of Timp4 gene deletion on hepatic steatosis could also be due to the decreased insulin levels in HFD-fed mice as insulin is a potent activator of hepatic lipogenesis. In addition, Timp4 −/− -HFD mice do not exhibit hypercholesterolemia mainly due to lower LDL-cholesterol levels, suggesting a possible role of TIMP4 in cholesterol metabolism. Decreased VLDL secretion may be responsible for the observed decrease in the LDL-cholesterol levels as VLDL particles transform to LDL particles upon TG delivery to the peripheral tissues.
In summary, our study demonstrates that absence of TIMP4 suppresses HFD-induced obesity possibly by impairing lipid absorption. This can further hinder the complications associated with obesity including hepatic steatosis, dyslipidemia, as well as adipocyte hypertrophy, inflammation, and fibrosis. Considering the multiple protective effects of Timp4 gene deletion against obesity and associated comorbidities, targeted inhibition of TIMP4 could be a promising therapeutic target against obesity.
